Upload
letizia-belli
View
225
Download
5
Embed Size (px)
Citation preview
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizioneDiego Peroni
U.O.S. Allergologia Pediatrica
Azienda Ospedaliera Universitaria
Integrata Verona [email protected]
Orticaria cronica- Angioedema
Orticaria associata o meno a angioedema che dura per più di 6-8 settimane con sintomatologia quotidiana.
Orticaria
Angioedema Pomfo: lesione cutanea evanescente, con centro edematoso, pallido e margini iperemici. Interessa gli strati superficiali del derma.
Edema per stravaso capillare dai vasi del derma profondo o del sottocute
LTC5a
Istamina
Orticaria associata o meno a angioedema che dura per più di 6-8 settimane con sintomatologia quotidiana.
Orticaria
Angioedema Pomfo: lesione cutanea evanescente, con centro edematoso, pallido e margini iperemici. Interessa gli strati superficiali del derma.
Edema per stravaso capillare dai vasi del derma profondo o del sottocute
LTC5a
Istamina
80% dei casi di orticaria cronica presenta lesioni
da orticaria associate a
angioedema.
Orticaria cronica- Angioedema
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’orticaria acuta
• Almeno un episodio di orticaria acuta nella vita con prevalenza del 15-20% nella popolazione generale
• Una causa evidenziata in meno del 50% dei casi:
• 40% postinfettiva• 10% FANS• 1% alimenti
• Un alimento è sospettato nel 63% dei casi, ma viene dimostrato solo nell’1%
November 2012
Terapia orticaria
EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. T. Zuberbier, R. Asero et al. Allergy 2009: 64: 1417–1426
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’orticaria acuta
L’orticaria
cronica
La diagnosi
Orticaria cronica
Orticaria associata a angioedema che dura da più di 6-8 settimane ….
Orticaria
Angioedema Pomfo: lesione cutanea evanescente, con centro edematoso, pallido e margini iperemici. Interessa gli strati superficiali del derma.
Edema per stravaso capillare dai vasi del derma profondo o del sottocute
LTC5a
Istamina
Orticaria Cronica:Diagnosi Eziologica
Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review
Martina M. et al. J Am Acad Dermatol 2003
1° valutazione:
• Anamnesi
• Esame obiettivo (se presenti valutare le lesioni cutanee)
• Somministrare questionario e consegnare diario giornaliero
• Test per dermografismo
• Emocromo, VES, PCR.
• Prescrivere antistaminici
• Informare genitori del carattere benigno della malattia
• Informare i genitori che nella maggior parte dei casi la causa
rimane ignota
DIARIO - ORTICARIA
Giorno
Terapia in corso
Assunzione di cibi
Assunzione di farmaci
Prurito
Dolore
Altri sintomi(febbre, g.e, artralgia)
Estensione
Durata
Luogo e situazione(sport, doccia ..)
Data e ora
Nome del paziente ……………………...
Settimana dal…………. al ……………..
BSACI guidelines for the management of chronic urticaria and angio-oedema. R. J. Powell. CEA, 2007; 37, 631–650.
2° valutazione:
• Valutazione andamento clinico (visione diario)
• Esame obiettivo
• Esecuzione esami diagnostici di 2° livello in base ai dati
raccolti.
• Eventuale sospensione di farmaci considerati triggers.
• Prescrivere antistaminici (eventuale progressione negli step
terapeutici).
Orticaria cronicaDiagnosi eziologica
Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review
Martina M. J Am Acad Dermatol 2003
Esami diagnostici di 2° livello – BSACI guidelines. CEA 2007
Eziologia Che esami
Idiopatica (40-50%) Indagini negative
Autoimmune ANA, ab antitiroide, ASST
Da stimolo fisico Challenge con lo stimolo appropriato
Da farmaci Sospensione (beneficio settimane-mesi)
Infezioni Sierologie in base alla storia clinica
Allergia SPTs, ImmunoCAP
Deficit C1 esterasi-inibitore
C4, C1 inibitore (Ag., Funz.)
Vasculite ANCA, ANA, C3, Ig, sierologie epatite, funzionalita’ epatica e renale, biopsia cutanea
Pat. linfoproliferativa Paraproteine
Additivi alimentari Esclusione e reintroduzione
..ma non dimentichiamoaltre cause di Orticaria….
• Pseudoallergeni (conservanti, coloranti, additivi).
• Infezione da Helicobacter Pylori.
• Infezioni parassitarie.
• Infezioni delle vie urinarie.
• Celiachia.
• Manifestazione iniziale di malattie reumatologiche sistemiche (JRA, SLE).
L’ OC rappresenta spesso il sintomo di esordio.
BSACI guidelines for the management of chronic urticaria and angio-oedema
R. J. Powell. CEA 2007; 37, 631–650.
Patogenesi di asma e CU esacerbati da FANS
Cutaneous Reactions to Aspirin and Nonsteroidal Antiinflammatory DrugsMario Sánchez-Borges, Clinical Reviews in Allergy & Immunology Volume 24, 2003
AsmaUrticaria
angioedema
FANS e COX 1 inibitori
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’orticaria acuta
L’orticaria
cronica
La diagnosi
Le nuove [email protected]
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Cugno Intern Emerg Med; 2010, 5:97
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Cugno Intern Emerg Med; 2010, 5:97
Mechanisms of eosinophil and mast cell activation in chronic urticaria (CU).
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Cugno Intern Emerg Med; 2010, 5:97
Mechanisms of eosinophil and mast cell activation in chronic urticaria (CU).
Mast cells release histamine and other inflammatorymediators after stimulation by autoantibodies directed against the high-affinity IgE receptor (FceRI) and IgE, complement anaphylatoxin C5a, eosinophil-derived major basic protein (MBP) andpossibly other molecules
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Cugno Intern Emerg Med; 2010, 5:97
Mechanisms of eosinophil and mast cell activation in chronic urticaria (CU).
Eosinophils are activated by autoantibodies directed against the low-affinity IgE receptor (FceRII) and potentially by other factors, release MBP and express tissue factor which in turn activates the coagulation cascade (factors VII, X, V and prothrombin)leading to thrombin generation.
Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications
Cugno Intern Emerg Med; 2010, 5:97
Mechanisms of eosinophil and mast cell activation in chronic urticaria (CU).
Eosinophils are activated by autoantibodies directed against the low-affinity IgE receptor (FceRII) and potentiallyby other factors, release MBP and express tissue factor which in turn activates the coagulation cascade (factors VII, X, V and prothrombin)leading to thrombin generation.
Thrombin generation is demonstrated in CU patients
by the increased plasma levels of the fragment F1+2 released
from prothrombin after its activation. Finally, fibrin
degradation is documented by elevated plasma levels of
the fibrin fragment D-dimer in CU patients with
active disease
Effetto della trombina
Trombina
Vasodilatazione
Produzione di mediatori infiammatori
Attivazione diretta di C5a bypassando C3
Attivazione diretta degranulazione mastocitaria
• Circa il 50% dei pazienti con
Orticaria cronica idiopatica
presenta ASST + ma:
• In circa il 50% non c’ è
corrispondenza tra test in vivo e in
vitro;
• Decomplementazione e deplezione
di IgG dal siero non riducono la
capacità di indurre reazione in
vivo;
• Il 50% delle orticarie idiopatiche
rimane comunque inspiegato.
ASST - Autologous Serum Skin Test -
Pathogenesis of chronic urticaria A. P. Kaplan Clin Exp All, 2009, 39, 777
• Circa il 50% dei pazienti con
Orticaria cronica idiopatica
presente ASST + ma:
• In circa il 50% non c’ è
corrispondenza tra test in vivo e in
vitro;
• Decomplementazione e deplezione
di IgG dal siero non riducono la
capacità di indurre reazione in
vivo;
• Il 50% delle orticarie idiopatiche
rimane comunque inspiegato.
ASST - Autologous Serum Skin Test -
Pathogenesis of chronic urticaria A. P. Kaplan Clin Exp All, 2009, 39, 777
Altri fattori istaminoliberatori potrebbero essere
implicati nella patogenesi della
malattia.
Orticaria cronica, ASST, APST e HRA
• Orticaria cronica• APST positivo nel 75-
85% dei casi• ASST positivo nel 50-
60% dei casi • HRA positivo nel 25-
30% dei casi
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’orticaria acuta
L’orticaria
cronica
La diagnosi
Le nuove evidenze
La terapia
Terapia orticaria cronica
EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. T. Zuberbier, R. Asero et al. Allergy 2009: 64: 1417–1426
EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining
diagnostic criteria. Konstantinou GN Allergy 2013
Circumstantial evidence for CU being an autoimmune disease comes from
an observed association with other autoimmune diseases,
a strong association between serum functionality and HLA-DR4 haplotype and
the good response of CU patients to immunotherapies
Chronic urticaria and autoimmunity: Associations found in a large
population study Confino-Cohen, JACI 2012;129:1307
12,778 patients with CU during 17 years in a large health maintenance organization.
A control group of 10,714 patients who had no CU.
17.3
6% Rheumato
id arthritis
28.8
13.2
Hyper-thyroidis
m
Hypo-thyroidis
m
In patients with CU OR for
30 –
25 –
20 –
15 –
10 –
05 –
0
Chronic urticaria and autoimmunity: Associations found in a large
population study Confino-Cohen, JACI 2012;129:1307
15.2
6% Systemi
c LE
26.9
14.6
Celiac disease
Sjögren syndro
me
In patients with CU OR for
30 –
25 –
20 –
15 –
10 –
05 –
0
7.7
Type I diabete
s mellitus
12,778 patients with CU during 17 years in a large health maintenance organization.
A control group of 10,714 patients who had no CU.
EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining
diagnostic criteriaKonstantinou G. N, Allergy 2013;68:27-36
Chronic urticaria (CU).
Approximately 25% of CU patients have a positive basophil histamine release assay and show autoreactivity (a positive autologous serum skin test), whereas 50% are negative regarding both.
Basophil activation by CU sera is predominantly restricted to IgG1 and IgG3 subclasses.
Circumstantial evidence for CU being an autoimmune disease comes from an observed association with other autoimmune diseases, a strong association between serum functionality and HLA-DR4 haplotype and the good response of CU patients to immunotherapies.
EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining
diagnostic criteriaKonstantinou G. N, Allergy 2013;68:27-36
How not to miss autoinflammatory diseases masquerading as urticaria
Krause K, Allergy 2012;67:1465-1474
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’orticaria acuta
L’orticaria
cronica
La diagnosi
Le nuove evidenze
Il caso clinico
P.P 5 aa e 6 mesi APR:
- Otiti ricorrenti;
- Bronchiti asmatiformi ricorrenti;
- Autismo.
20/12/2011
Otite Amoxicillina comparsa di rash orticarioide Cetirizina 0.25 mg/kg + Bentelan 4 mg/die
Peggioramento orticaria PS a BZ: Deltacortene 15 mg/die
Visita allergologica BZ:
Controllo esami ematici: TAS 329IU/ml, resto normale.
Allergia agli acari.
Scalo deltacortene a 5 mg 2.5 mg/die + Augmentin (MT iperemiche + TAS elevato).
Profilassi ambientale.
2 visite dermatologiche BZ dieta bianca senza nessun beneficio
Peggioramento PS BZ:
Augmentin Zinnat;
Zirtec Aerius + Fenistil la sera
Ancora deltacortene 2.5 mg
Persistenza del quadro:
10/02/2012: PS VR.
MT dx iperemica e bombata:
Deltacortene 2.5 mg/die
Aerius + Fenistil
Singulair
Orelox (OM persistente).
DH allergologia 20/02/2012
Totale:
• 2 mesi di sintomi continui.
• 2 mesi di CSO;
• 8 visite specialistiche;
• 4 Abt diverse.
DH allergologia 20/02/2012
APST +
• Immunoglobuline: nella norma;
• Sierologie HBV, HCV, EBV, Parvovirus B19: nella norma;
• Ricerca parassiti fecali: neg;• Ab antigliadina anti TG: neg;• Ricerca HP Pylori nelle feci:
neg. • D-dimero: 1.2 mg/l .
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’angioedema
I meccanismi
BSACI guidelines for the management of chronic urticaria and angio-oedema. R. J. Powell. CEA, 2007; 37, 631–650.
Hereditary angio-oedema. Longhurst H. Lancet 2012; 379:474
Angio-oedema of hand
Capsule endoscopy during abdominal attack
Erythema marginatum on anterior chest wall
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Cugno M, Trends in Molecular Medicine, 2009; 15: 69Simplified representation of the kinin system. Bradykinin is generated through the cleavage of high molecular weight kininogen (HK) by plasma kallikrein during contact-system activation
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Cugno M, Trends in Molecular Medicine, 2009; 15: 69
The most important inhibitor of the contact system is C1-INH, which inactivates kallikrein and FXIIa.
Bradykinin is degraded by peptidases, such as human kininase I, also called carboxypeptidase N, and kininase II, also called angiotensinconverting enzyme (ACE).
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Cugno M, Trends in Molecular Medicine, 2009; 15: 69
Representation of the pathogenesis of angioedema due to C1-INH deficiency
In HAE, the deficiency of C1-INH is due to a mutation in the C1-INH gene, whichimpairs C1-INH synthesis or function. In AAE, C1-INH deficiency is due to the cleavage of C1-INH by autoantibodies or to its consumption by neoplastic, mainlylymphoproliferative, tissue.
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Cugno M, Trends in Molecular Medicine, 2009; 15: 69
Representation of the pathogenesis of angioedema due to C1-INH deficiency
Reduced C1-INH plasma levels result in hyperactivation of the classical complement pathway with increased consumption of C1-INH and furtherreduction of its plasma level.
Hereditary angio-oedema. Longhurst H. Lancet 2012; 379:474
Criteria for diagnosis of hereditary angio-oedema
Type III hereditary angioedema: defined, but not understood. Kaplan, Ann Allergy Asthma
Immunol 2012;109:153
1) Type III hereditary angioedema (HAE) is a familial form of angioedema in which complement C4 and C1 inhibitor (C1 INH) protein and function are normal.
2) Most patients are women, although an occasional male is identified, and a close association with estrogen as a precipitant of attacks of angioedema is seen (contraception, postmenopausal symptom control).
3) Like types I and II HAE, angioedema is recurrent, it is not associated with urticaria, and it is unresponsive to antihistamines or corticosteroids.
Type III hereditary angioedema: defined, but not understood. Kaplan, Ann Allergy Asthma
Immunol 2012;109:153
1) Type III hereditary angioedema (HAE) is a familial form of angioedema in which complement C4 and C1 inhibitor (C1 INH) protein and function are normal.
2) Most patients are women, although an occasional male is identified, and a close association with estrogen as a precipitant of attacks of angioedema is seen (contraception, postmenopausal symptom control).
3) Like types I and II HAE, angioedema is recurrent, it is not associated with urticaria, and it is unresponsive to antihistamines or corticosteroids.
We do not have a test that can be used to
make the diagnosis.
Type III hereditary angioedema: defined, but not understood. Kaplan, Ann Allergy Asthma
Immunol 2012;109:153
1) Type III hereditary angioedema (HAE) is a familial form of angioedema in which complement C4 and C1 inhibitor (C1 INH) protein and function are normal.
2) Most patients are women, although an occasional male is identified, and a close association with estrogen as a precipitant of attacks of angioedema is seen (contraception, postmenopausal symptom control).
3) Like types I and II HAE, angioedema is recurrent, it is not associated with urticaria, and it is unresponsive to antihistamines or corticosteroids.
Overproduction of bradykinin is assumed,
but not proven.
Type III hereditary angioedema: defined, but not understood. Kaplan, Ann Allergy Asthma
Immunol 2012;109:153
a) A mutation in factor XII, exon 9 consisting of either Thr 309 lys or Thr 309 arg has been associated with type III HAE patients, and, although specific for this disorder, it is found only in 25-30% of patients whose swelling is unexplained but is clearly familial.
b) The mutation was reported to cause excessive conversion of prekallikrein to kallikrein and was described as a “gain of function” mutation.
Clinical, biochemical, and genetic characterization of type III hereditary angioedema in
13 Northwest Spanish families. Marcos, Ann Allergy Asthma Immunol 2012;109:195
Population with type III hereditary angioedema.
29 patients (26 female, 3 male).
1) 22 of these patients had the estrogen-dependent phenotype.
2) All had functional C1 inhibitor activity within the normal range in periods without high estrogen levels, but during attacks (in female patients) and pregnancy, activity decreased to below 50%.
3) The C4 and antigenic C1 inhibitor levels were always normal.
Population with type III hereditary angioedema.
29 patients (26 female, 3 male).
1) 22 of these patients had the estrogen-dependent phenotype.
2) All had functional C1 inhibitor activity within the normal range in periods without high estrogen levels, but during attacks (in female patients) and pregnancy, activity decreased to below 50%.
3) The C4 and antigenic C1 inhibitor levels were always normal.
All studied patients had the c.1032C>A, Thr309Lys mutation
in the factor XII gene.
Clinical, biochemical, and genetic characterization of type III hereditary angioedema in
13 Northwest Spanish families. Marcos, Ann Allergy Asthma Immunol 2012;109:195
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’angioedema
I meccanismi
La terapia
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Cugno M, Trends in Molecular Medicine, 2009; 15: 69
Current and potentially new treatments for angioedema due to hereditary or acquired C1-INH deficiency
Terapia angioedema
Terapia attacco acuto Terapia cronica profilattica
• Berinert (pdC1- INH pastorizzato, liofilizzato concentrato);
• Ecallantide (inibitore della Kallikreina);
• Icatibant (antagonista competitivo di BK2R);
• Rhucin (C1-INH ricombinante umano)
• Androgeni blandi:
• Danazolo
• Stanazolo
• Metiltestosterone
• Antifibrinolitici
FPP (fresh frozen plasma)
SDP (solvent detergent- treated plasma)
• Idratazione,
• Antidolorifici,
Effetti collaterali
pdcC1 INH umano, indicato per gli attachi acuti di HAE con interessamento addominale, facciale e laringeo negli adulti e negli adolescenti.
Le manifestazioni allergologiche particolari:
Orticaria / Angioedema
La definizione
L’angioedema
I meccanismi
La terapia
Il caso clinico
Angioedema – Francesca 4 anni
Accesso al PS per comparsa di edema importante a livello dell’arto sup di sinPregressa faringite trattata con Amox-ClavulFamiliarita’ per angioedema ereditario (madre)
E.O.Edema a livello della mano e avambraccio di sin, cute calda, pallida. Non doloreRx avambraccio e mano: non lesioni ossee a focolaioEcodoppler: pervio l’asse venoso succlavio-ascellare-omerale. Diffuso infarcimento dei tessuti molliComplemento C4 0.04 g/L (vn 0.10-0.40), C1 inibitore 0.06 g/L (vn 0.15-0.35)
Conclusioni: Angioedema ereditarioSi consiglia visita specialistica presso la Clinica Medica MilanoIn caso di emergenza Berinert f. 500 UI
C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress.
Cugno M, Trends in Molecular Medicine, 2009; 15: 69
Le manifestazioni allergologiche particolari:
Le sindromi da attivazione mastocitaria
Diego Peroni
U.O.S. Allergologia Pediatrica
Azienda Ospedaliera Universitaria
Integrata Verona [email protected]
Characteristics of human mast cell subsets
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
Selected mast cell activators of clinical relevance
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
(1) degranulation with resulting release of preformed mediators stored in granules, including histamine, heparin, proteases, and cytokines, such as TNF-a;
(2) De novo synthesis of arachidonic acid metabolites (most notably prostaglandin D2 and leukotriene C4) from membrane lipids;
(3) synthesis and secretion of cytokines and chemokines
Activation of mast cells results in
The mast cell
Mast cell
activation
syndrome
MCAS, SM or MMCA
Le manifestazioni allergologiche particolari:
Le sindromi da attivazione mastocitaria
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
Disease states associated with evidence of mast cell activation
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099Classification of diseases associated with mast cell activation
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099Signs and symptoms suggested to potentially occur in MCAS or mast cell activation disorder
These symptoms are attributed tomast cell degranulation in mastocytosis, and those with mast cell activation disorder/MCAS are said to have many of the same symptoms.
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
MCAS as a distinct clinical entity has not been generally accepted, nor do there exist definitive criteria for diagnosis.
Based on current understanding of this disease ‘‘syndrome’’ and on what we do know about mast cell activation and resulting pathology, we will explore and propose criteria for its diagnosis.
The diagnostic standard for systemic mastocytosis has been the demonstration
of:
Major criterion
• multifocal mast cell clusters of atypical
morphology in a bone marrow biopsy specimen.
The minor diagnostic criteria
• a tryptase level of greater than 20 ng/mL,
• atypical (spindle-shaped and hypogranulated)
mast cell morphology,
• aberrant expression of CD2 and CD25 on mast
cells,
• detection of a codon 816 mutation in c-Kit.
WHO classification of tumours of haematopoietic and lymphoid tissues. Horny HP, Lyon:IARC Press; 2008. p. 54-63.
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
Proposed criteria for the diagnosis of MCAS
1.Episodic symptoms consistent with mast cell mediator release affecting >2 organ systems evidenced as follows:
a. Skin: urticaria, angioedema, flushingb. Gastrointestinal: nausea, vomiting, diarrhea,
abdominal crampingc. Cardiovascular: hypotensive syncope or near
syncope, tachycardiad. Respiratory: wheezinge. Naso-ocular: conjunctival injection, pruritus,
nasal stuffiness Plus
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
Proposed criteria for the diagnosis of MCAS
2. A decrease in the frequency or severity or resolution of symptoms with antimediator therapy: H1- and H2-histamine receptor agonists,
antileukotriene medications (cysteinyl leukotriene receptor blockers or 5-lipoxygenase inhibitor), or mast cell stabilizers (cromolyn sodium)
3. Evidence of an increase in a validated urinary or serum marker of mast cell activation: documentation of an increase of the marker to greater than the patient’s baseline value during a symptomatic period on >2 occasions or, if baseline tryptase levels are persistently >15 ng, documentation of an increase of the tryptase level above baseline value on 1 occasion. Total serum tryptase level is recommended as the marker of choice; less specific (also from basophils) are 24-hour urine histamine metabolites or PGD2 or its metabolite 11-b-prostaglandin F2.
4. Rule out primary and secondary causes of mast cell activation and well-defined clinical idiopathic entities
Mast cell activation syndrome: Proposed diagnostic criteria. Akin C, JACI; 2010; 126:1099
Proposed criteria for the diagnosis of MCAS
2. A decrease in the frequency or severity or resolution of symptoms with antimediator therapy: H1- and H2-histamine receptor agonists,
antileukotriene medications (cysteinyl leukotriene receptor blockers or 5-lipoxygenase inhibitor), or mast cell stabilizers (cromolyn sodium)
3. Evidence of an increase in a validated urinary or serum marker of mast cell activation: documentation of an increase of the marker to greater than the patient’s baseline value during a symptomatic period on >2 occasions or, if baseline tryptase levels are persistently >15 ng, documentation of an increase of the tryptase level above baseline value on 1 occasion. Total serum tryptase level is recommended as the marker of choice; less specific (also from basophils) are 24-hour urine histamine metabolites or PGD2 or its metabolite 11-b-prostaglandin F2.
4. Rule out primary and secondary causes of mast cell activation and well-defined clinical idiopathic entities
MCAS for now remains an idiopathic disorder; however, in some cases it could be an
early reflection of a monoclonal population of
mast cells, in which case with time it could
meet the criteria for MMAS as 1 or 2 minor criteria for
mastocytosis are fulfilled
MCAS for now remains an idiopathic disorder; however, in some cases it could be an
early reflection of a monoclonal population of
mast cells, in which case with time it could
meet the criteria for MMAS as 1 or 2 minor criteria for
mastocytosis are fulfilled